secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001628280-24-048673
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions sells CBS unit to Standex for $6.1M, records $2M in stock comp and $1.5M debt repayment
--------------------------------------------------------------------------------

- Sold Custom Biogenic Systems (CBS) to Standex International for ~$6.1M; transaction closed Nov 14, 2024.
- Incurred $2.0M compensation expense from accelerated share vesting for CBS employees; repaid ~$1.5M of CBS debt.
- CBS results classified as discontinued operations; pro forma shows revenue reduction of ~$10.2M for 9mo 2024 and ~$13.6M for FY2023.
- Pro forma combined with prior SciSafe sale yields continuing ops net income of $6.9M for 9mo 2024 vs historical net loss $32.6M.
- Entered transition services agreement with CBS post-closing; two-year non-compete covenant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024048673/0001628280-24-048673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024048673/blfs-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-048673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer